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Abstract The maturation of lamin A is completed by the 
endoproteolytic cleavage of its farnesylated precursor protein, 
prelamin A. In the absence of this cleavage, prelamin A can 
neither give rise to lamin A nor assemble into the nuclear lamina. 
We call the enzyme which catalyzes this endoproteolytic step the 
'prelamin A endoprotease'. In this study, we begin characteriza-
tion of the regulation of prelamin A endoprotease. In particular, 
we address the question as to whether prelamin A endoprotease 
activity is constitutive in cells or responds to expression of 
prelamin A. To do this, we compared the activity of this novel 
endoprotease in cells which express prelamin A with those that 
do not. Our data shows that the enzymatic activity of prelamin A 
endoprotease is enhanced by the expression of prelamin A. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The nuclear lamina is composed of three major, intermedi-
ate filament proteins lamin A, B and C [1,2]. Lamin A is 
synthesized as a precursor protein, prelamin A [3]. Prela-
min A and lamin B, but not lamin C, possess a 'CAAX' con-
sensus sequence at their carboxyl-terminal [4,5]. There are 
three sequential post-translational modifications of the car-
boxyl terminal 'CAAX' motif [6]. These three steps are farne-
syl modification of the cysteine residue, endoproteolytic re-
moval of the AAX group, and methylation of the carboxyl 
group of the now carboxyl terminal farnesylated cysteine res-
idue [7]. Following these post-translational modifications, 
prelamin A undergoes a further endoproteolytic cleavage to 
complete the formation of mature lamin A [8-11] which is 
now competent for assembly into the nuclear lamina [1,12]. 
This cleavage occurs between Y657 and L658 of prelamin A. 
In a prior report [8], we have pointed out that there is 
a consensus sequence in the prelamin A molecule, 
RSY657L658LG, conserved across several species, around this 
cleavage site which does not occur in any other known pro-
tein. This simple hexapeptide was demonstrated to be a sub-
strate for the prelamin A endoprotease, confirming its func-
tional significance in conferring specificity. These observations 
are consistent with the hypothesis that prelamin A endopro-
tease is a novel enzyme, which may not be active with other 
naturally occurring substrates. If so, it might be expected that 
the activity of the prelamin A endoprotease may be correlated 
with expression of prelamin A. 
In this paper, we initiate the analysis of the regulation of 
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prelamin A endoprotease and test this hypothesis. It has been 
observed that prelamin A is not expressed in embryonic cells 
[13] or in a number of rapidly proliferating tissues such as 
lymphoid tissue, and epithelial cells of lung, kidney, liver 
and intestine [14]. Here, we compare the prelamin A endopro-
tease activity of hemopoietic, HL60 promyelocytic leukemia 
cells and F9 teratocarcinoma cells which lack expression of A/ 
C lamins [15,16], with HeLa cells that expresses high levels of 
A/C lamins. We then go on to examine the effect of expression 
of prelamin A in F9 cells on the prelamin A endoprotease 
activity of such cells. Our results indicate that the activity of 
this enzyme is enhanced by the expression of prelamin A. 
2. Materials and methods 
2.1. Cells and antibodies 
The cells used in these studies were HeLa (cultured in Ham's F12 
medium supplemented with 10% fetal calf serum (v/v; FCS), 100 U/ml 
penicillin, 100 |0,g/ml streptomycin and 1 ug/ml amphotericin B), F9 
mouse teratocarcinoma cells (grown in F12 supplemented with 15% 
FCS) and HL60 promyelocytic leukemia cells (RPMI supplemented 
with 20% FCS). F9LA and F9A21 are F9 derived cell lines which 
express human prelamin A or mature lamin A under the control of 
the control of the mouse mammary tumor virus promoter [17,18]. 
F9LA and F9A21 cells were treated with 1X 10~7 M dexamethasone 
to induce the expression of human prelamin A or lamin A [17,18]. 
A rabbit polyclonal anti-human prelamin A specific antiserum 
(a-PA) which was generated against a synthetic peptide, CLLGNSS-
PRTQSPQN [19]; a-A/C, a non-species specific polyclonal antibody 
specific for A/C lamin (kind gift of Dr. Nilabh Chaudhary, Triplex 
Pharmaceutical); and 1E4(20) a species specific anti-human lamin A 
antibody (kind gift of Dr. F. McKeon, Harvard Medical School) were 
used in this study. 
2.2. Prelamin A endoprotease assay 
The prelamin A endoprotease assay was performed essentially as 
previously described [8]. Briefly, cell pellets were resuspended to a final 
density of 4X 108 cells/ml in ice-cold lysis buffer (0.01 M Tris-HCl, pH 
7.0, 0.01 M NaCl, 3 mM MgCl2, 0.4% NP-40). Nuclei were isolated 
after two more washes, in the same buffer, and pelleting by centrifu-
gation in a Sorvall HB-4 rotor for 10 min at 365 Xg. The nuclei were 
resuspended in the same buffer without NP-40. Protein concentration 
was obtained by means of the Micro BCA Protein Assay Reagent Kit 
(Pierce Chemical, Rockford, IL). 
The endoprotease reaction was initiated by the addition of 125I-
RSY* LLG to the nuclear extract in a final volume of 20 u.1 in 10 
mM MES, pH 6.0. The reaction was run for 20 min at 37°C and 
stopped by the addition of 5 ul of glacial acetic acid and chilling on 
ice for 10 min. The reaction mixture was applied to reverse-phase thin 
layer chromatography (TLC) plates (Analtech, Inc. Newark, DE). 
TLC plates were developed in 10% acetonitrile in water and the spots 
visualized by autoradiography. The reaction product was identified by 
its co-migration with a synthetic, iodinated RSY* peptide standard. 
The amount of labeled RSY formed in the assay was determined by 
scraping the appropriate spots into tubes and quantitation of radio-
activity with a gamma counter. 
2.3. Western blotting 
F9 and F9LA cell lysates were resolved on 4-20% linear gradient 
SDS-PAGE, transferred to a polyvinylidene difluoride (PVDF) mem-
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branes and probed with 1:200 diluted a-A/C antibody. After washes 
in TBS containing 0.1% Tween 20, the membrane were incubated with 
horseradish peroxidase-conjugated anti-rabbit (Amersham Corp.) IgG 
(1:5000 dilution) for 1 h. Detection of the immunosignal was done 
using ECL Western blotting detection system (Amersham Corp.). 
2.4. Immunofluorescence 
Cells were plated on coverslips and incubated overnight. They were 
then fixed in 3% formaldehyde in PBS for 15 min and permeabilized 
with 0.05% Triton X-100 in PBS for 10 min at room temperature. The 
coverslips were then washed three times in 5 mM NH4CI in PBS. 
Prelamin A or lamin A were visualized by incubating for 1 h with 
either cc-PA or 1E4 at 1:200 dilution followed by Texas red-conju-
gated goat anti-rabbit (Biomeda; 1:500) IgG (H+L) or sheep anti-
mouse (Cappell, diluted 1:25) respectively. 
3. Results 
3.1. Enzymatic activity of prelamin A endoprotease in HeLa, 
F9 and HL60 cells 
As we previously described [8], the hexapeptide, R S Y L L G 
behaves as an appropriate substrate for the prelamin A endo-
protease. Therefore in this study, the endoproteolytic activity 
of prelamin A endoprotease was assayed in vitro by reacting 
RSY 
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Fig. 1. Assay of prelamin A endoprotease activity. A: Autoradio-
graphic visualization of reverse-phase TLC separation of reaction 
products. Lane 1: synthetic radio-iodinated RSY*; lanes 2-4: HeLa 
nuclei; lanes 5-7: F9 nuclei; and lanes 8-10: HL60 nuclei are as-
sayed for endoprotease activity by formation of radio-iodinated 
RSY as described under Section 2. The radio-labeled material at the 
solvent front co-migrates with iodotyrosine. The nuclei used in these 
assays corresponded to 3 uig of protein. B: The quantitation of the 
reaction product RSY*. The activity of prelamin A endoprotease is 
calculated following the detection of the reaction product on the 
film. The results are the average of 3 determinations. 
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Fig. 2. The prelamin A endoprotease assay in HeLa, F9 and HL60 
cells is linear with protein. The endoprotease assay is performed 
with 3, 6, 9 and 12 |j,g nuclear protein from HeLa (circle with plus), 
F9 (triangle with circle) and HL60 (filled hexagon) cells. Each point 
is the average of two determinations. 
Fig. 3. Dexamethasone-inducible expression of human prelamin and 
lamin A in F9LA cells. Immunofluorescent visualization of prelamin 
A in mevinolin-treated F9LA cells in the presence (A) or absence 
(B) of 10~7 M dexamethasone treatment overnight. When F9LA 
cells were fixed and stained with a human specific anti-lamin A anti-
body (1E4) dexamethasone-inducible expression of human lamin A 
could be detected (C).There was no staining in the absence of dexa-
methasone (D). 
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Fig. 4. Expression of the lamin A precursor up regulates the activity 
of prelamin A endoprotease. The prelamin A endoprotease is as-
sayed in F9 cells which are permanently transfected with dexame-
thasone inducible constructs expressing lamin A (F9A21) and its 
precursor protein (F9LA). Control experiments demonstrate that 
dexamethasone treatment has no effect on prelamin A endoprotease 
activity in the parental F9 cells. The results shown are the average 
of 3 determinations. 
the radioiodinated synthetic peptide 125I-RSY* LLG with the 
crude nuclei from three cell lines: HeLa which express prel-
amin A, and HL60 and F9 cells which do not express prela-
min A. The reaction mixture was resolved by reverse-phase 
TLC and visualized by autoradiography (Fig. 1A). The cleav-
age product of prelamin A endoprotease was followed by its 
co-migration with radio-iodinated RSY* synthetic peptide, as 
described before [8]. After quantitation of the amount of 
RSY* formed by means of y-counting, the enzymatic activity 
of prelamin A endoprotease in HL60 and F9 cells was found 
to be 9 times less than the activity in HeLa cells (Fig. IB). We 
also confirmed the linearity of the prelamin A endoprotease 
assay with protein in these cells (Fig. 2). These observations 
are in agreement with the hypothesis that prelamin A endo-
protease activity may be regulated by prelamin A expression. 
observed only in cells treated with dexamethasone (Fig. 
3C,D). 
Parental F9, F9LA and F9A21 cells were assayed for prel-
amin A endoprotease activity in the presence or absence of 
dexamethasone supplementation. Only in the F9LA cells, 
which express prelamin A, was a significant response of prel-
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3.2. Expression of lamin A precursor enhances the activity of 
prelamin A endoprotease 
At this point, it was not obvious whether the variation in 
the prelamin A endoprotease activity occurred as a result of 
cell type or the expression of prelamin A. To distinguish be-
tween these possibilities, we utilized F9 cells permanently 
transfected with human prelamin A (F9LA) or lamin A 
(F9A21) constructs [17,18], which permits dexamethasone in-
duction of prelamin or lamin A. 
The dexamethasone induction of lamin A or prelamin A in 
F9LA cells is shown in Fig. 3. Following its synthesis, prel-
amin A continuously gives rise to mature lamin A. As we 
have demonstrated previously [11,18], prelamin A accumu-
lates in the nuclei of cells treated with lovastatin, an inhibitor 
of mevalonate biosynthesis and, hence, the farnesylation de-
pendent processing of prelamin A. Nuclear staining with oc-
PA is observed in lovastatin-treated F9LA cells only in the 
presence of dexamethasone (Fig. 3A,B). To demonstrate that 
this material was of transgenic origin, F9LA cells were also 
stained with human specific anti-lamin A (1E4). Staining was 
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Fig. 5. Dose-response of prelamin A endoprotease and prelamin A 
to dexamethasone in F9 and F9LA cells. A: Autoradiographic visu-
alization of reverse-phase TLC isolation of RSY peptide formed in 
response to various concentrations of dexamethasone. Cells were 
treated with 10"8, 2X10"8, 5X10"8 or 10"7 M dexamethasone 
overnight and the nuclear extracts were prepared for in vitro assay. 
Lanes \-A: F9 nuclei; lanes 5-8: F9LA nuclei are assayed for endo-
protease activity by formation of radio-iodinated RSY as described 
under Section 2. B: The quantitation of the reaction product RSY*. 
The activity of prelamin A endoprotease is calculated following the 
detection of the reaction product on the film. C: Concentration de-
pendent dexamethasone-inducible lamin A expression in F9LA cells. 
F9LA cells were treated with 1(T8, 2X10"8, 5X10"8 or 10"7 M 
dexamethasone (lanes 1-4) overnight. The cell lysates were run on 
SDS-PAGE and lamin A is visualized by immunoblotting with lam-
in A/C antibody (oe-A/C). 
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amin A endoprotease activity observed to dexamethasone 
(Fig. 4). To more clearly correlate prelamin A endoprotease 
activity with the extent of expression of prelamin A, F9 and 
F9LA cells were treated with various concentrations of dex-
amethasone. The results indicate that prelamin A endopro-
tease activity is dose-responsive to dexamethasone treatment 
(Fig. 5A,B) in the same concentration range (10_ 8-10 - 7 M) as 
is prelamin A expression (Fig. 5C). 
4. Discussion 
Following farnesylation and the other canonical CAAX 
box post-translational modifications, the lamin A precursor 
must undergo a further proteolytic cleavage to give rise to 
lamin A. The functional significance of prelamin A endopro-
teolysis in the formation and assembly of lamin A into the 
nuclear lamina has been described previously by our labora-
tory and others [3,8,19,20]. However, before this study, no 
data was available regarding possible regulation of the endo-
protease. 
To understand the effect of the expression of lamin A pre-
cursor on the enzymatic activity of prelamin A endoprotease, 
we assayed this enzyme in cell lines which do and do not 
express the lamin A precursor. It has previously been noted 
that expression of prelamin A in embryonal carcinoma cells 
which do not express the lamin A gene still results in the 
assembly and processing of the precursor [17,21,22]. We found 
large differences in prelamin A endoprotease activity between 
cells that normally express or do not express lamin A. Our 
experiments suggest that the ability of cells to process trans-
genic prelamin A depends, in part, on up-regulation of the 
prelamin A endoprotease, which, in turn, appears to be regu-
lated by the level of prelamin A expression. 
These results may also be relevant to the question of sub-
strate specificity of the prelamin A endoprotease. Based on 
the primary structural constraints for recognition of substrate 
by the prelamin A endoprotease that we have previously de-
scribed and the apparent uniqueness of those features (farne-
sylation and the RSYLLG motif) to prelamin A, it would 
appear plausible that this enzymes functions solely to process 
prelamin A. The up-regulation of this enzyme by prelamin A 
that we report here is also consistent with this specificity for 
prelamin A. 
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